NMN works at a cellular level over weeks of consistent use. It is not a stimulant. Here is what customers report, and when. Individual results vary.
NMNH (Dihydronicotinamide Mononucleotide, also written beta-NMNH or β-NMNH) is the reduced form of NMN (Nicotinamide Mononucleotide). Standard NMN — the oxidised form — must first be reduced to NMNH by cellular enzymes before NMNAT (nicotinamide mononucleotide adenylyltransferase) can catalyse the final step of NAD+ synthesis. NMNH enters this pathway directly as the immediate NMNAT substrate — one step closer to the NAD+ end product.
NMNH is the direct substrate for NMNAT — the enzyme that completes NAD+ synthesis. NMN must first be reduced to NMNH. NMNH skips that conversion step entirely.
500mg NMNH per serving — matched to doses used in published research on Dihydronicotinamide Mononucleotide. >99% purity verified by third-party testing every batch.
NMNH → NAD+ via NMNAT (nicotinamide mononucleotide adenylyltransferase). No intermediate conversion from oxidised to reduced form required.
Standard NMN (β-Nicotinamide Mononucleotide) is the oxidised form of the molecule. Before it can be used by NMNAT to synthesise NAD+, it must first be reduced to NMNH by cellular enzymes.
NMNH — Dihydronicotinamide Mononucleotide, also written as β-NMNH — is the reduced form. It enters the NMNAT pathway directly, without requiring the prior reduction step. This is the theoretical basis for NMNH as a next-generation NAD+ precursor.
Research documents an approximate 50% fall in cellular NAD⁺ between age 20 and 50. NMNH (Dihydronicotinamide Mononucleotide) is the reduced form of NMN — one metabolic step closer to NAD+ in the biosynthesis pathway, utilised directly by NMNAT without prior enzymatic reduction.
NMNH: the direct substrate for NMNAT — the enzyme that completes NAD+ synthesis from the mononucleotide form. Where NMN requires enzymatic reduction before NMNAT can act, NMNH does not. This is the theoretical case for NMNH as a next-generation NAD+ precursor.
Read: What is NAD⁺? →| Parameter | Spec | Result |
|---|---|---|
| NMNH identity | β-NMNH confirmed | PASS |
| NMNH purity | >99% | 99.3% |
| NMNH potency | 500mg/serv | 501mg |
| Heavy metals | Below limit | PASS |
| Microbial | Below limit | PASS |
| Gluten (ELISA) | <20ppm | PASS |
Before a single pouch leaves our facility, every batch is sent to an independent ISO/IEC 17025-accredited laboratory for analysis. If it fails any specification, it doesn't ship.
One ingredient. The next-generation NAD+ precursor form. >99% purity. Third-party verified every batch.
NMNH (β-Dihydronicotinamide Mononucleotide) is the reduced form of NMN. The oxidised form of NMN (β-NMN) must first be reduced by cellular enzymes before it can be used by NMNAT (nicotinamide mononucleotide adenylyltransferase) to synthesise NAD+. NMNH bypasses this reduction step — entering the NMNAT pathway directly as the immediate substrate for NAD+ synthesis.
The theoretical advantage is straightforward: fewer enzymatic conversion steps between the supplement and the NAD+ end product. Research on NMNH is newer and less extensive than the established body of NMN literature, but mechanistic data supports its role as a direct NAD+ precursor. At 500mg per serving, Vitality NMNH is formulated at the dose used in emerging research.
| Ingredient | Per serving | NRV |
|---|---|---|
| NMNH (β-Dihydronicotinamide Mononucleotide) | 500 mg | † |
How NMNH (Dihydronicotinamide Mononucleotide) compares to standard NMN and other NAD+ precursors available in the UK (May 2026).
| Feature | Vitality NMNH | Standard NMN supplements |
|---|---|---|
| Form of molecule | ✓ NMNH — reduced form (β-Dihydronicotinamide Mononucleotide) | NMN — oxidised form (β-Nicotinamide Mononucleotide) |
| Steps to NAD+ | ✓ Direct NMNAT substrate — no prior reduction required | Must first be reduced to NMNH before NMNAT can act |
| Biosynthesis pathway position | ✓ One step closer to NAD+ | One step further from NAD+ |
| Research maturity | Emerging — mechanistic data supports role as direct NAD+ precursor | 30+ published human studies — more established evidence base |
| Dose per serving | ✓ 500mg β-NMNH — >99% purity | Varies — 125mg to 1000mg, purity often unverified |
| Third-party tested per batch | ✓ Every batch, ISO/IEC 17025 accredited | ✗ Rarely per-batch |
| UK manufacturing | ✓ UK manufactured | Often overseas |
| Money-back guarantee | ✓ 60-day satisfaction guarantee | Varies — often 14 days or none |
A full year of next-generation NAD+ support. Our lowest per-day price — 55p/day.
The emerging evidence on NMNH points to one thing above all: consistency. A full year's supply removes the decision entirely — your batch is reserved, your price is locked, and you never run out mid-protocol.
I'd been on NMN for two years and decided to try NMNH based on the mechanistic argument — the reduced form bypassing the conversion step makes theoretical sense. It's been 8 weeks now. Hard to compare directly but energy consistency has been good. Quality and packaging are excellent.
Vitality don't oversell NMNH — the product page is honest about the research being newer than NMN. That transparency is actually what convinced me. >99% purity, ISO-tested, UK made. I've tried three other brands and none were this transparent about what's actually in the capsule.
500mg per serving at this price point, with a proper batch test behind it — that's genuinely hard to find for NMNH. Most products I found were either underdosed or came with no evidence of third-party testing. On my second order now.
Our guides cover the science, the research, and the protocol decisions — written for people who want to understand what they're taking.
NMNH (Dihydronicotinamide Mononucleotide, also written β-NMNH) is the reduced form of NMN (β-Nicotinamide Mononucleotide). Standard NMN — the oxidised form — must first be reduced by cellular enzymes to NMNH before it can be used by NMNAT (nicotinamide mononucleotide adenylyltransferase) to synthesise NAD+. NMNH bypasses this reduction step, entering the NMNAT pathway directly as the immediate substrate for NAD+ synthesis.
The theoretical advantage is one fewer enzymatic conversion step between supplementation and NAD+ production. Research on NMNH is newer and less extensive than the established NMN literature. This is a food supplement, not a medicine, and is not intended to diagnose, treat, cure or prevent any disease.
NMNH research is newer and less extensive than the 30+ year body of human clinical data on AHCC, or the 10+ year published NMN literature. The mechanistic basis for NMNH as a direct NAD+ precursor is scientifically sound — the biosynthesis pathway is well characterised and NMNH's position in it as the direct NMNAT substrate is established biochemistry. Published studies on NMNH as a supplement are emerging. We are honest about this on this page — we do not overstate the clinical evidence. The theoretical case is strong; the human trial data is building.
This is a genuinely open question. NMN has a more extensive human clinical evidence base — multiple randomised controlled trials, safety data to 1,200mg/day, and a longer record of use. NMNH has a theoretically more efficient pathway to NAD+ but a smaller body of published human data. For someone new to NAD+ precursor supplementation, NMN is the better-evidenced starting point. NMNH is suited to people who understand the mechanistic argument and want to trial the next-generation form. Vitality offers both — NMN + Resveratrol for the established protocol, and NMNH for those specifically seeking the reduced precursor form.
500mg NMNH per serving (2 capsules). This is the dose used in emerging published research on Dihydronicotinamide Mononucleotide and is consistent with the doses being studied in ongoing trials. Purity is verified at >99% by third-party testing on every batch.
NMNH is not a stimulant and does not produce immediate effects. Like NMN, it works at a cellular level over weeks of consistent use. Most customers report first changes around weeks 4–8. The 60-day guarantee covers this full assessment timeline. Individual responses vary based on age, baseline NAD+ status and consistency of use. These are customer-reported experiences, not guaranteed outcomes.
Yes. Vegan HPMC plant-derived capsule shell. 100% vegan, gluten-free, dairy-free, soy-free, nut-free, non-GMO. UK manufactured.
Take 2 capsules in the morning, with or without food. Consistency of daily dosing matters more than precise timing. If you take prescription medication, consult your GP before adding any supplement.
The safety profile of NMNH at 500mg/day is consistent with published NMN safety data at comparable doses — NMN trials have reported no significant adverse events at doses up to 1,200mg/day (Yi et al. 2022). NMNH is structurally very similar and has the same established safety pattern at the doses studied. If pregnant, breastfeeding or on prescription medication, consult a healthcare professional before use. This product is a food supplement, not a medicine.
Every batch independently tested by an ISO/IEC 17025-accredited laboratory. Identity confirmed as β-Dihydronicotinamide Mononucleotide, potency verified at 500mg per serving, heavy metals and microbial testing included. Certificate of Analysis available on request — email info@vitalitysupplements.co.uk with your batch number.
Yes. NMNH is a permitted food supplement ingredient in the United Kingdom, regulated under the Food Supplements (England) Regulations 2003 and overseen by the Food Standards Agency (FSA). It is not a controlled substance, not a prescription medicine, and is not subject to any MHRA restriction on sale as a food supplement.
60-day satisfaction guarantee. Email info@vitalitysupplements.co.uk within 60 days with your order number for a full refund. Your statutory rights under the Consumer Rights Act 2015 apply.
NMNH and NMN address the same NAD+ precursor pathway — taking both simultaneously is redundant, choose one. NMNH is commonly combined with TMG (Trimethylglycine) to support the methylation demands that NAD+ precursor supplementation creates, and with other longevity compounds including Resveratrol, Pterostilbene or Apigenin without widely reported interactions. If you take prescription medication — particularly immunosuppressants, blood thinners or diabetes medication — consult your GP before adding any supplement.
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme central to energy metabolism, mitochondrial function, DNA repair and the activation of sirtuin proteins. Research documents an approximate 50% decline in cellular NAD+ between the ages of 20 and 50 — a decline associated with reduced mitochondrial efficiency and impaired DNA repair capacity.
NMNH is a direct NAD+ precursor. It enters the biosynthesis pathway as the immediate substrate for NMNAT (nicotinamide mononucleotide adenylyltransferase) — the enzyme that converts mononucleotides to NAD+. This is a food supplement providing a NAD+ precursor molecule, not a medicine, and is not intended to diagnose, treat, cure or prevent any disease.
Subscribe and save 10%. 60-day satisfaction guarantee. Free UK delivery on all orders.
